Junshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%

MT Newswires Live09-27

Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock Exchange.

Nanjing JSIAMA Biopharmaceuticals granted the pharmaceutical company the right to conduct research, develop, manufacture, and sell the product in the Greater China region. Both parties will share the interests of the product.

JunTop will pay JSIAMA upfront payments worth 40 million yuan, research and development fees within China of 240 million yuan, and another $150 million for research and development milestones outside China.

JSIAMA will also receive a single-digit percentage sales-based royalties on the annual net sales of the nasal spray, the Chinese pharmaceutical company said.

The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.

Price (HKD): $13.46, Change: $+1.2, Percent Change: +10.15%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470740875?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-27 13:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470740875","market":"sh","top_or_hot":-1,"title":"Junshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%","media":"MT Newswires Live","content":"<html><body><p> Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock Exchange.</p><p>Nanjing JSIAMA Biopharmaceuticals granted the pharmaceutical company the right to conduct research, develop, manufacture, and sell the product in the Greater China region. Both parties will share the interests of the product.</p><p>JunTop will pay JSIAMA upfront payments worth 40 million yuan, research and development fees within China of 240 million yuan, and another $150 million for research and development milestones outside China.</p><p>JSIAMA will also receive a single-digit percentage sales-based royalties on the annual net sales of the nasal spray, the Chinese pharmaceutical company said.</p><p>The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.</p><p>Price (HKD): $13.46, Change: $+1.2, Percent Change: +10.15%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Biosciences Gets Rights for IAMA-001 Nasal Spray in Greater China; Shares Soar 10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-27 13:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470740875","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470740875","pubTimestamp":1727413594,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Junshi Biosciences'  unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock Exchange.Nanjing JSIAMA Biopharmaceuticals granted the pharmaceutical company the right to conduct research, develop, manufacture, and sell the product in the Greater China region. Both parties will share the interests of the product.JunTop will pay JSIAMA upfront payments worth 40 million yuan, research and development fees within China of 240 million yuan, and another $150 million for research and development milestones outside China.JSIAMA will also receive a single-digit percentage sales-based royalties on the annual net sales of the nasal spray, the Chinese pharmaceutical company said.The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.Price : $13.46, Change: $+1.2, Percent Change: +10.15%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4588":"碎股","HKD":"尚乘数科","BK4023":"应用软件","BK1583":"高瓴概念","01877":"君实生物","BK4526":"热门中概股","BK0239":"医药制造"},"translate_title":"君实生物获得IAMA-001鼻喷剂大中华区权益；股价飙升10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"HKD":1,"01877":0.9},"content_text":"Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) unit, Shanghai JunTop Biosciences, received the exclusive license of IAMA-001 nasal spray, according to a Thursday disclosure on the Hong Kong Stock Exchange.Nanjing JSIAMA Biopharmaceuticals granted the pharmaceutical company the right to conduct research, develop, manufacture, and sell the product in the Greater China region. Both parties will share the interests of the product.JunTop will pay JSIAMA upfront payments worth 40 million yuan, research and development fees within China of 240 million yuan, and another $150 million for research and development milestones outside China.JSIAMA will also receive a single-digit percentage sales-based royalties on the annual net sales of the nasal spray, the Chinese pharmaceutical company said.The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.Price (HKD): $13.46, Change: $+1.2, Percent Change: +10.15%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470740875"}